Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Philip O. Buck"'
Autor:
Karen Fowler, Jacek Mucha, Monika Neumann, Witold Lewandowski, Magdalena Kaczanowska, Maciej Grys, Elvira Schmidt, Andrew Natenshon, Carla Talarico, Philip O. Buck, John Diaz-Decaro
Publikováno v:
BMC Public Health, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Background Cytomegalovirus (CMV) is a common pathogen that affects individuals of all ages and establishes lifelong latency. Although CMV is typically asymptomatic in healthy individuals, infection during pregnancy or in immunocompromised in
Externí odkaz:
https://doaj.org/article/44123ed7f23f40c984013c2e95c217d8
Autor:
Philip O. Buck, Dumingu Aparna Gomes, Ekkehard Beck, Noam Kirson, Matthew Mattera, Stuart Carroll, Bernhard Ultsch, Kavisha Jayasundara, Mathieu Uhart, Louis P. Garrison, Jr.
Publikováno v:
Vaccines, Vol 12, Iss 3, p 234 (2024)
The COVID-19 pandemic’s dramatic impact has been a vivid reminder that vaccines—especially in the context of infectious respiratory viruses—provide enormous societal value, well beyond the healthcare system perspective which anchors most Health
Externí odkaz:
https://doaj.org/article/7952172987994499adfb351a5b30b4ed
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 3871-3875 (2021)
In early 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. In response, two novel messenger RNA (mRNA)-based vaccines: mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) were rapidl
Externí odkaz:
https://doaj.org/article/d7f0789f3b8449bdbf3f5ff1bca6b3ea
Autor:
Oscar Herrera-Restrepo, Kimberly Davis, Carolyn Sweeney, Eric Davenport, Parinaz Ghaswalla, Philip O. Buck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
This study aimed to evaluate the attitudes and practices of US healthcare professionals (HCPs) regarding the Advisory Committee on Immunization Practices (ACIP) vaccination recommendations on HepA and HepB for adult patients at risk of contracting th
Externí odkaz:
https://doaj.org/article/affb00aefe254b7e9da0d5953a151485
Autor:
Brandon J. Patterson, Chi-Chang Chen, Catherine B. McGuiness, Lisa I. Glasser, Kainan Sun, Philip O. Buck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 8, Pp 2482-2487 (2021)
Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United States (US) for the prevention of herpes zoster in adults aged 50 years and older. The vaccine is administered in two doses, with the second dose administration rec
Externí odkaz:
https://doaj.org/article/bd2f14ee610347a897c679c0756248fc
Autor:
Brandon J. Patterson, PharmD, PhD, Philip O. Buck, PhD, MPH, Desmond Curran, PhD, Desirée Van Oorschot, MSc, Justin Carrico, BS, William L. Herring, PhD, Yuanhui Zhang, PhD, Jeffrey J. Stoddard, MD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 3, Pp 596-604 (2021)
Objective: To investigate the potential public health impact of adult herpes zoster (HZ) vaccination with the adjuvanted recombinant zoster vaccine (RZV) in the United States in the first 15 years after launch. Methods: We used a publicly available m
Externí odkaz:
https://doaj.org/article/db6d36ff1baa4e9fac9d525a5a16522a
Autor:
Amber Hsiao, Philip O. Buck, Arnold Yee, John Hansen, Edwin M. Lewis, Laurie L. Aukes, Emad Yanni, Rafik Bekkat-Berkani, Anne Schuind, Nicola P. Klein
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 8, Pp 1753-1761 (2020)
In children 39°C, acute otitis media, lower respiratory tract infection (LRTI), or extra-pulmonary complications; otherwise, they were classified as mild. We used multivariable log-binomial models to assess whether M-S influenza disease was associat
Externí odkaz:
https://doaj.org/article/5acc4b57c32e4eecb44623e1af1c36a4
Autor:
Michelle McNamara, Philip O. Buck, Songkai Yan, Leonard R. Friedland, Kristin Lerch, Alysa Murphy, Cosmina Hogea
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 9, Pp 2217-2226 (2019)
This study evaluated physician practices and perceived barriers for influenza, tetanus, diphtheria, pertussis (Tdap), and zoster vaccination of adults in the United States (US), with emphasis on patients with Medicare versus commercial insurance. A c
Externí odkaz:
https://doaj.org/article/0129690906644808a4f92b2abfaee96e
Autor:
Desmond Curran, Brandon J. Patterson, Desiree Van Oorschot, Philip O. Buck, Justin Carrico, Katherine A. Hicks, Bruce Lee, Barbara P. Yawn
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 4, Pp 765-771 (2019)
Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committe
Externí odkaz:
https://doaj.org/article/e32a74a9e71e4cde9b0d2cb2e3ab1819
Autor:
Girishanthy Krishnarajah, Elisabetta Malangone-Monaco, Liisa Palmer, Ellen Riehle, Philip O. Buck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 12, Pp 2932-2939 (2018)
Background: In the United States (US), diphtheria, tetanus, and acellular pertussis (DTaP) vaccination is recommended at 2, 4, and 6 months (doses 1–3), 15–18 months (dose 4), and 4–6 years (dose 5). The objective of this study (GSK study ident
Externí odkaz:
https://doaj.org/article/5b4f3c862fa1404ca35ad591286f4375